TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26857949
Drug: Nebulized albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized albuterol (10 mg over 1 hour)
Study: 18371487
Drug: Darbepoetin alpha
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alpha (1.5 microg/kg every 20 days for 3 months) plus oral iron
Study: 19361602
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus oral iron
Study: 16817918
Drug: Hyoscine butylbromide
Normalized name: Hyoscine butylbromide
DrugBank: Butylscopolamine (DB09300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine butylbromide 10 mg t.d.s.
Study: 16817918
Drug: Paracetamol 500
Normalized name: Paracetamol 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 500 mg t.d.s.
Study: 16817918
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of hyoscine and paracetamol
Study: 15013050
Drug: VPA 125
Normalized name: VPA 125 MG Delayed Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: VPA 125 mg per day
Study: 15013050
Drug: VPA 250
Normalized name: VPA 250 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: VPA 250 mg per day
Study: 15013050
Drug: VPA 375
Normalized name: VPA
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VPA 375 mg per day
Study: 15013050
Drug: VPA 500
Normalized name: VPA 500 MG Delayed Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: VPA 500 mg per day
Study: 15013050
Drug: VPA (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: VPA (all doses)
Study: 3012808
Drug: Clindamycin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (600 mg) every six hours and tobramycin (1.5 mg/kg) every eight hours
Study: 23328235
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional treatment for metastatic lymph nodes in Group B (13 patients)
Study: 20801120
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of lansoprazole twice daily
Study: 18727689
Drug: Antidepressants (AD)
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (AD) + mood stabilizer (MS)
Study: 15537676
Drug: Ketamine (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (two doses of intravenous ketamine)
Study: 12682003
Drug: Intracoronary abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary abciximab (20 mg bolus)
Study: 12682003
Drug: Intravenous abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous abciximab (20 mg bolus)
Study: 8728459
Drug: High-velocity, low-amplitude
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-velocity, low-amplitude cervical manipulation twice a week for 3 weeks
Study: 8728459
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser in the upper cervical region and deep friction massage in the lower cervical/upper thoracic region, twice a week for 3 weeks
Study: 6345374
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg nifedipine
Study: 2243148
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg nifedipine
Study: 6345374
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of nifedipine (20 mg, 40 mg, 60 mg)
Study: 31556824
Drug: Motivational interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational interviewing (MoI) intervention with initial counseling call and up to 2 monthly follow-up calls by pharmacy students trained in MoI.
Study: 27574437
Drug: Vildagliptin 50
Normalized name: vildagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 50 mg once daily (qd) or twice daily (bid)
Study: 11952200
Drug: Couples-Based Psychoeducational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Couples-Based Psychoeducational Attention Control Treatment (PACT)
Study: 28062087
Drug: SeB (Sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: SeB (Sequential Boost) of 10Gy in 4 fractions or 14.88Gy in 6 fractions
Study: 23460656
Drug: Extended cognitive‐behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended cognitive‐behavioral treatment with 9 additional group sessions over a 14‐week period
Study: 23460656
Drug: Nonextended treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonextended treatment with 4 monthly smoking status calls
Study: 21560485
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg of salbutamol nebulized via oxygen (or compressed air)
Study: 2665304
Drug: Transthoracal injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transthoracal injections of 0.5% solution of papain
Study: 2665304
Drug: Active antiinflammatory
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active antiinflammatory therapy and bronchosanitation measures
Study: 28483190
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment once per week for 10 weeks
Study: 10351466
Drug: Bi-annual, house-to-house
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bi-annual, house-to-house re-treatment schedule free of charge using research project staff
Study: 10351466
Drug: Free re-treatment
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free re-treatment service via sentinel dipping stations
Study: 10351466
Drug: Social marketing
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social marketing approach with cost-retrieval for net re-treatment services
Study: 7564436
Drug: External papaverine
Approvals — FDA: no, EMA: no, PMDA: no
Description: External papaverine application (1.5 mg/ml)
Study: 7564436
Drug: Intraluminal papaverine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraluminal papaverine application with heparinized blood (1.5 mg/ml) injected once
Study: 7564436
Drug: Intraluminal papaverine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraluminal papaverine application with heparinized blood (1.5 mg/ml) injected twice
Study: 7564436
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (submersion in papaverine solution only)
Study: 6113993
Drug: 2.5 gm
Normalized name: Avycaz 2.5 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 gm of 5% nonoxynol‐9 vaginal cream (Conceptrol) for 14 days
Study: 6113993
Drug: 2.5 gm
Normalized name: Avycaz 2.5 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 gm of the cream base alone for 14 days
Study: 31543350
Drug: Ranibizumab treatment
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab treatment in BRVO
Study: 31543350
Drug: Ranibizumab treatment
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab treatment in CRVO
Study: 25022125
Drug: Transcutaneous electrical
Normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous electrical acupoint stimulation combined with infusion of propofol (group A)
Study: 20878849
Drug: Prescription sedative/hypnotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription sedative/hypnotics
Study: 22763497
Drug: OTC analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTC analgesics
Study: 18720067
Drug: Combined surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined surgical and corticosteroid treatment (oral prednisolone for 10 days, nasal budesonide for 1 month, followed by nasal steroids for 1 year)
Study: 18720067
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment alone (not specified in detail)
Study: 18720067
Drug: Combined surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined surgical and corticosteroid treatment
Study: 15454647
Drug: Supportive care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive care plus cisplatin-based chemotherapy (C)
Study: 9879412
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 300 mg/day suplatast tosilate alone
Study: 9879412
Drug: Immunotherapy using
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy using standardized D. farinae alone
Study: 9879412
Drug: Immunotherapy together
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy together with concurrent oral administration of 300 mg/day suplatast tosilate
Study: 1357451
Drug: Clodronate 2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 2.4 g daily for 24 months
Study: 30198102
Drug: Dutasteride 0.5
Normalized name: dutasteride 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 0.5 mg + tamsulosin 0.2 mg
Study: 26651495
Drug: Itraconazole 400
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole 400 mg daily for 7 days/month (two pulses for fingernails and three pulses for toenails)
Study: 26651495
Drug: Terbinafine 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 500 mg daily for 7 days/month (two pulses for fingernails and three pulses for toenails)
Study: 26634453
Drug: Subcutaneous injections
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections of botulinum toxin type A
Study: 24184035
Drug: Hydroxychloroquine niosomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine niosomal gel formulation (20mg in 20% w/v Pluronic F‐127 gel), applied once daily for 4 months
Study: 19265345
Drug: 3‐mL conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3‐mL conventional syringe
Study: 19265345
Drug: 10‐mL conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐mL conventional syringe
Study: 19265345
Drug: 3‐mL RPD
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3‐mL RPD
Study: 19265345
Drug: 10‐mL RPD
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐mL RPD
Study: 9497117
Drug: Non-invasive electrical
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-invasive electrical stimulation, performed at home for one hour daily for a mean period of 45 days
Study: 1411408
Drug: Nitrendipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (20 mg/d)
Study: 7514874
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 mg/d)
Study: 12195873
Drug: Norfloxacin 400
Normalized name: norfloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin 400 mg b.i.d.
Study: 3074464
Drug: Co-trimoxazole (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (160 mg trimethoprim + 800 mg sulphamethoxazole) b.i.d.
Study: 29769203
Drug: DPP-IV inhibitor
Normalized name: Dipeptidyl peptidase 4 (DPP-4) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPP-IV inhibitor alogliptin (early period up to 6 months)
Study: 29769203
Drug: DPP-IV inhibitor
Normalized name: Dipeptidyl peptidase 4 (DPP-4) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPP-IV inhibitor alogliptin (chronic period 6 months to end of follow-up)
Study: 16155272
Drug: Calcium supplement
Normalized name: Calcium supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplement (450 mg)
Study: 10494457
Drug: CI-988 100
Normalized name: CI 77266
DrugBank: Carbon black (DB11980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CI-988 100 mg TID for six weeks
Study: 1848169
Drug: L-arginine hydrochloride
DrugBank: L-arginine (DB17289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine hydrochloride (0.5 g h-1 kg-1 body weight)
Study: 1848169
Drug: L-lysine hydrochloride
Normalized name: L-lysine hydrochloride
DrugBank: Lysine (DB00123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-lysine hydrochloride (0.44 g h-1 kg-1 body weight)
Study: 29604599
Drug: Garlic extract
Normalized name: Garlic Extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic extract (GE) 400 mg daily for 3 months
Study: 25015436
Drug: Valsartan/Amlodipine immediate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan/Amlodipine immediate release tablets (film-coated)
Study: 17352516
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 or 200mg once daily
Study: 20205490
Drug: Sitagliptin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin monotherapy
Study: 17352516
Drug: Sitagliptin as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin as add-on therapy to metformin or pioglitazone
Study: 17352516
Drug: Sitagliptin as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin as add-on therapy to metformin
Study: 15111779
Drug: Daily iron
Normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iron supplementation (1 mg/kg daily)
Study: 15111779
Drug: Weekly iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly iron supplementation (7 mg/kg weekly)
Study: 15111779
Drug: Weekly group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly group
Study: 15111779
Drug: Daily and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily and control groups
Study: 11157138
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy (15 days i.v. followed by 21 days oral)
Study: 9626844
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy with nitrates and atenolol or verapamil
Study: 355024
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (untreated patients)
Study: 31453877
Drug: Volatile inhalational
Normalized name: Peppermint volatile oil
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volatile inhalational agents (desflurane or sevoflurane)
Study: 31547446
Drug: Twice the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice the RDA (2RDA: 1.6 g protein/kg bodyweight/day)
Study: 31547446
Drug: Twice the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice the RDA (2RDA)
Study: 31547446
Drug: Recommended dietary
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended dietary allowance (RDA: 0.8 g protein/kg bodyweight/day)
Study: 28544241
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 400 IU of RRR‐alpha‐tocopherol
Study: 28544241
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of serum levels between treatment and control groups
Study: 23899829
Drug: Aerobic training-estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerobic training-estrogen therapy (AT-ET)
Study: 23899829
Drug: Sedentary-estrogen therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedentary-estrogen therapy (SED-ET)
Study: 21853229
Drug: Intravitreal triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal triamcinolone acetonide (IVTA) 4 mg
Study: 19651674
Drug: L-arginine (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (9 g/day)
Study: 19651674
Drug: Creatine (21
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine (21 g/day)
Study: 19651674
Drug: L-arginine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine plus creatine
Study: 17463412
Drug: Roflumilast (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast (500 microg once daily)
Study: 10211537
Drug: Sparfloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparfloxacin (400 mg on day 1, then 200 mg once daily for 9 days)
Study: 10211537
Drug: Clarithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (500 mg twice daily for 14 days)
Study: 2533449
Drug: Gestrinone 2.5
Normalized name: gestrinone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestrinone 2.5 mg twice weekly
Study: 29173736
Drug: Stimulant plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant plus Parent Training (PT)
Study: 26001318
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion at nil μg kg(‐1) min(‐1)
Study: 26001318
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion at 0.05 μg kg(‐1) min(‐1)
Study: 26001318
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion at 0.10 μg kg(‐1) min(‐1)
Study: 26001318
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion at 0.15 μg kg(‐1) min(‐1)
Study: 26001318
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion at 0.20 μg kg(‐1) min(‐1)
Study: 26001318
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion at 0.25 μg kg(‐1) min(‐1)
Study: 19010636
Drug: 4 cc
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 cc fibrin glue after RILND
Study: 14747423
Drug: Quinapril (high-tissue-penetrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (high-tissue-penetrating ACE inhibitor)
Study: 14747423
Drug: Enalapril (low-tissue-penetrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (low-tissue-penetrating ACE inhibitor)
Study: 1842749
Drug: Miglitol, 50
Normalized name: Miglitol, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miglitol, 50 mg three times a day
Study: 342626
Drug: Whole-virus bivalent
Normalized name: INFLUENZA A VIRUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-virus bivalent influenza vaccine
Study: 342626
Drug: Ether-split bivalent
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ether-split bivalent influenza vaccine
Study: 27883203
Drug: Platform-switched implant-abutment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platform-switched implant-abutment connection
Study: 27883203
Drug: Conventional platform-matched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional platform-matched implant-abutment connection
Study: 15195074
Drug: Busulphan (BU)
Normalized name: Busulphan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulphan (BU) 150 mg/m2 given as four single daily doses
Study: 15195074
Drug: Busulphan (BU)
Normalized name: Busulphan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulphan (BU) 4 mg/kg given as four single daily doses
Study: 10367611
Drug: Active antihypertensive
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active antihypertensive medication
Study: 10319538
Drug: Ketotifen 2
Normalized name: ketotifen 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen 2 mg
Study: 1323811
Drug: Preoperative Cisplatin/Etoposide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative Cisplatin/Etoposide with concurrent thoracic irradiation
Study: 6507909
Drug: Midazolam hydrochloride
Normalized name: Midazolam Hydrochloride
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam hydrochloride (5 mg/ml)
Study: 6507909
Drug: Midazolam maleate
Normalized name: midazolam maleate
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam maleate (2.5 mg/ml)
Study: 20581689
Drug: High CRP
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High CRP (>3 mg/L)
Study: 21784046
Drug: Individualized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized treatment (24-72 weeks)
Study: 21784046
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (48 weeks)
Study: 21784046
Drug: Individualized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized treatment (24-30 weeks) for rapid responders
Study: 21784046
Drug: Individualized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized treatment (60-72 weeks) for slow responders
Study: 17177749
Drug: Intense pulsed
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense pulsed light (IPL) treatment with retinyl-based cream
Study: 17177749
Drug: Intense pulsed
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense pulsed light (IPL) treatment only
Study: 13679494
Drug: Tertatolol (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tertatolol (5-10 mg/day)
Study: 8638692
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no rhGH treatment)
Study: 1587426
Drug: Oral erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral erythromycin (500 mg)
Study: 1420750
Drug: Intravenous erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous erythromycin (1.8 mg/kg)
Study: 1420750
Drug: Oral erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral erythromycin (500 mg) b.d.
Study: 20452749
Drug: Psychosocial treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial treatment
Study: 15121485
Drug: Aprepitant 10
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant 10 mg
Study: 21397770
Drug: Besifloxacin ophthalmic
Normalized name: besifloxacin ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days